Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:51:04.315Z.
Calculation as of: 2026-10-06T12:51:04.315Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7e5dd7cae71be814523bfc9444594aa14e5919ebae0d9bfc7936539f469f7652
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Cerenome, Inc.
Market Cap
$10.74M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Cerenome, Inc. (CNSY) | $10.74M | N/A |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.27M | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $10.07M | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.41M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | N/A |
| Ainos, Inc. (AIMD)vs › | $9.79M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | N/A |
| HeartSciences Inc. (HSCS)vs › | $9.42M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
